Fragile X syndrome clinical trial in Australia seeking participants aged 3-17 years

September 10th, 2021

A new research study by Zynerba Pharmaceuticals is enrolling children and adolescents aged 3 to 17 years of age and who have Fragile X syndrome and are also experiencing behavioural-related issues.
This clinical trial is valuating investigational cannabidiol (CBD) gel in children and adolescents to assess whether it helps behavioural issues related to Fragile X syndrome, such as social anxiety, irritability and social unresponsiveness.

The study is enrolling participants in sites across several countries including Australia and the United States.  In Australia the enrolment sites are in Melbourne, Brisbane and Sydney, as was the case for the earlier Zynerba studies.

More information:


You can help us make a difference

Fragile X Association of Australia is a registered charity, funded by donations and fundraising. Donations of $2.00 and over are tax deductible. Your donation will help us support families affected by Fragile X, and to increase awareness of Fragile X associated conditions.

Make a donation
Fragile X Logo
Registered Charity Logo